A Non-interventional Study for Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy. With Special Focus on Patients Who Are in Transition From First Line to Second Line Treatment
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- AstraZeneca
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- To obtain patient preferences in direct correlation with clinical data from patients suffering from NSCLC stage IIb/IV who are in transition from 1st line to 2nd line treatment
研究概览
简要总结
The main purpose of this study is the identification, description, and segmentation of non-small cell lung cancer (NSCLC) patients based on their value appraisal of treatment outcomes and all intermediate states of health, to obtain patient preferences in direct correlation with clinical data from patients suffering from NSCLC (stage IIIB / IV) who are in transition from 1st to 2nd line treatment, and to gain utility scores by health state derived from patients' perceived value and taken from their perspective.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients suffering from non-small cell lung cancer (NSCLC) with clinical stage IIIB and IV tumours
- •Patients with one chemotherapy regimen (first line treatment) (adjuvant chemotherapy following surgery is also regarded as first line treatment)
- •Patients who are in transition from first to second line treatment
- •Patients who signed an informed consent
排除标准
- •Chemotherapy naïve patients
- •Patients ever enrolled in clinical studies treating non-small cell lung cancer (NSCLC) with chemotherapy (during 1st and 2nd line chemotherapy)
- •Patients who ever had chemotherapy for an indication other than NSCLC
结局指标
主要结局
To obtain patient preferences in direct correlation with clinical data from patients suffering from NSCLC stage IIb/IV who are in transition from 1st line to 2nd line treatment
时间窗: once only, 4-6 weeks after switch from 1st to 2nd line chemotherapy
次要结局
- socioeconomic status and demographics patients' perception of their health status and treatment patient values and patient preferences(once only, 4-6 weeks after switch from 1st to 2nd line chemotherapy)
- current medical practice treatment objectives and modalities side effects(once only, 4-6 weeks after switch from 1st to 2nd line chemotherapy)